Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company is known for its use of epigenetic modulators, particularly histone deacetylase (HDAC) inhibitors, to enhance the effectiveness of immunotherapies and targeted treatments. Syndax's lead investigational drug, Axzagertib (formerly Entinostat), aims to improve outcomes in various cancers by modulating the tumor microenvironment and overcoming resistance mechanisms.
Company News
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Within the last quarter, Syndax Pharmaceuticals (NASDAQ:SNDX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 5 3 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targ...
Shares of SmileDirectClub, Syndax Pharmaceuticals, AMC and Chinese automakers were most active ahead of Monday's market open.
Syndax’s lead product candidates include SNDX-5613 and SNDX-6352. Click here to read about its growth prospects and my recommendation.